Literature DB >> 18362054

Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1.

Ozgur Duman1, Sebahat Ozdem, Doga Turkkahraman, Nihal Dundar Olgac, Firat Gungor, Senay Haspolat.   

Abstract

Some experimental studies suggested that there may be a bone formation defect rather than a disorder in bone resorption in patients NF1. The aim of this study was to determine bone mineral density (BMD) with dual-energy X-ray absorptiometry (DEXA) and investigate specific bone formation and bone resorption and bone turnover markers in children with NF1. Thirty-two children and adolescents (16 boys, 16 girls; 16 prepubertal, 16 pubertal) with NF1 were recruited. Their age ranged from 3 to 17 years. They were compared with matched healthy children. Dual-energy X-ray absorptiometry were applied to 26 patients and 27 controls. Nine of 32 subjects with NF1 had a skeletal abnormality. BMD of the lumbar spine, and femoral neck in NF1 patients significantly decreased compared to that of healthy subjects. They were also significantly decreased in pubertal patients when compared to pubertal controls and in prepubertal patients when compared to prepubertal controls. Patients with skeletal abnormalities were found to have significantly lower level of osteocalcin when compared to patients without skeletal abnormality. Other biochemical markers did not exhibit any difference between the groups. In conclusion, our findings suggest that bone formation markers rather than DEXA could be good predictors of skeletal abnormalities among NF1 patients. However, in our study the number of the NF1 patients with skeletal abnormality and the number of bone formation markers studied were all limited. It is appropriate to perform larger studies with other bone formation markers beside osteocalcin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362054     DOI: 10.1016/j.braindev.2008.02.002

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

1.  Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Authors:  Kiran S Choudhry; Monica Grover; Alyssa A Tran; E O'Brian Smith; Kenneth J Ellis; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2012-04-11       Impact factor: 4.797

2.  Bone mineral density in children and young adults with neurofibromatosis type 1.

Authors:  Maya B Lodish; Urania Dagalakis; Ninet Sinaii; Ethan Bornstein; Aerang Kim; Kelsey B Lokie; Andrea M Baldwin; James C Reynolds; Eva Dombi; Constantine A Stratakis; Brigitte C Widemann
Journal:  Endocr Relat Cancer       Date:  2012-11-19       Impact factor: 5.678

Review 3.  Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.

Authors:  S A Bowden; B L Foster
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

5.  Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.

Authors:  Ursula Pia Ferrara; Cristina Tortora; Carmen Rosano; Antonia Assunto; Alessandro Rossi; Stefano Pagano; Mariateresa Falco; Chiara Simeoli; Rosario Ferrigno; Alessandra D'Amico; Dario Di Salvio; Giuliana Cangemi; Rosario Pivonello; Pietro Strisciuglio; Daniela Melis
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.379

6.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

Review 7.  Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1.

Authors:  Angelos Kaspiris; Olga D Savvidou; Elias S Vasiliadis; Argyris C Hadjimichael; Dimitra Melissaridou; Stella Iliopoulou-Kosmadaki; Ilias D Iliopoulos; Evangelia Papadimitriou; Efstathios Chronopoulos
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.